Woodcock Becomes PCORI Board's First FDA Representative
Center for Drug Evaluation and Research director accepts six-year term on Board of Governors of the Patient-Centered Outcomes Research Institute, which funds comparative effectiveness studies.
You may also be interested in...
Amazon, Microsoft, IBM among those helping build new operations and innovation centers for the US FDA's safety surveillance system.
FDA has always described its role as stopping short of regulating the practice of medicine. When it comes to opioids, that is no longer the case.
Instead of creating new mandate, legislation tells FDA to outline how risk-benefit decisions could be influenced by a product's abuse potential under existing approval authority; final opioids package expected to reach the White House soon.